Polyclonal Anti-Vaccinia Virus (WR) B5R Protein, (antiserum, Rabbit)

Catalog No. NR-629

For research use only. Not for human use.

Contributor:

Gary H. Cohen, Ph.D., Professor and Chair, Department of Microbiology, School of Dental Medicine, University of Pennsylvania, Philadelphia, Pennsylvania and Roselyn J. Eisenberg, Ph.D., Professor, Department of Pathobiology, Head, Laboratories of Microbiology and Immunology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania

Product Description:

Antiserum to the B5R membrane glycoprotein of the Western Reserve (WR) strain of vaccinia virus was produced by immunization of rabbits with a recombinant form of the B5R protein.[1–3] Recombinant B5R is available as BEI Resources NR-546 and NR-2624.

Material Provided:

Each vial contains approximately 0.2 mL of rabbit polyclonal antiserum to the B5R protein of the Western Reserve (WR) strain of vaccinia virus.

Packaging/Storage:

NR-629 was packaged aseptically in screw-capped plastic cryovials. The product is provided frozen and should be stored at -20°C or colder immediately upon arrival.

Functional Activity:

NR-629 is specific to the B5R protein of vaccinia virus (WR) as determined by Western blot analysis and ELISA.

Citation:

Acknowledgment for publications should read "The following reagent was obtained through the NIH Biodefense and Emerging Infections Research Resources Repository, NIAID, NIH: Polyclonal Anti-Vaccinia Virus (WR) B5R Protein, (antiserum, Rabbit), NR-629."

Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 4th ed. Washington, DC: U.S. Government Printing Office, 1999. HHS Publication No. (CDC) 93-8395. This text is available online at www.cdc.gov/od/ohs/biosfty/bmbl4/bmbl4toc.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government make any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to negotiate a license. U.S. Government contractors may need a license before first commercial sale.

References:

1. Aldaz-Carroll, L., et al. "Epitope-Mapping Studies Define Two Major Neutralization Sites on the Vaccinia Virus Extracellular Enveloped Virus Glycoprotein B5R." J. Virol. 79 (2005): 6260–6271. PubMed: 15858010.
2. Lustig, S., et al. "Combinations of Polyclonal or Monoclonal Antibodies to Proteins of the Outer Membranes of the Two Infectious Forms of Vaccinia Virus Protect Mice against a Lethal Respiratory Challenge." J. Virol. 79 (2005): 13454–13462. PubMed: 16227266.
3. Fogg, C., et al. "Protective Immunity to Vaccinia Virus Induced by Vaccination with Multiple Recombinant Outer Membrane Proteins of Intracellular and Extracellular Virions." J. Virol. 78 (2004): 10230–10237. PubMed: 15367588.

ATCC® is a trademark of the American Type Culture Collection.

Biodefense and Emerging Infections Research Resources Repository
P.O. Box 4137
Manassas, VA 20108-4137 USA
www.beiresources.org

800-359-7370
Fax: 703-365-2898
E-mail: contact@beiresources.org